SCHEMBL5954840

SCHEMBL5954840

CCOC(=O)C(CC)Nc1cccc(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
MMP2 P08253 2/20 0.47
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
MMP9 P14780 1/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
GBA1 P04062 1/20 0.43
RAB9A P51151 1/20 0.43
PKM P14618 1/20 0.43
MME P08473 1/20 0.43
PTGES O14684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4460272 0.85 CA12 (0.49) MMP2CA12CA9CA14KMT2A
SCHEMBL4460275 0.85 CA12 (0.49) MMP2CA12CA9CA14KMT2A
SCHEMBL26415150 0.82 MAPT (0.54) POLBMMP2CA12CA9KMT2A
SCHEMBL2484626 0.81 KDM4E (0.47) POLBMMP2CA12CA9CA14
SCHEMBL13240783 0.81 KDM4E (0.47) POLBMMP2CA12CA9CA14
SCHEMBL4424175 0.77 DHODH (0.48) POLBMMP2KMT2AMEN1HTT
SCHEMBL2123271 0.76 MEN1 (0.56) POLBCA12CA9KMT2AMEN1
SCHEMBL11744132 0.76 MAPK1 (0.66) KMT2AMEN1HTTSMN1; SMN2LMNA
SCHEMBL13980908 0.75 AURKA (0.49) POLBCA12CA9KMT2AMEN1
SCHEMBL7714036 0.74 TP53 (0.50) CA12CA9KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LABORATOIRES FOURNIER S.A. (FR) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LIPC, CYP4F2, SLC5A2 POLB 4612/4885MMP2 1550/4885CA12 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.